Literature DB >> 10897013

Cancer risk and mortality in users of calcium channel blockers. A cohort study.

H T Sørensen1, J H Olsen, L Mellemkjaer, A Marie, F H Steffensen, J K McLaughlin, J A Baron.   

Abstract

BACKGROUND: Data regarding the association between the use of calcium channel blockers and cancer risk have been conflicting. In the current study, the authors examined the cancer risk and mortality in users of calcium channel blockers in North Jutland County, Denmark.
METHODS: The authors conducted a cohort study using record linkage between a population-based prescription database, the Danish Cancer Registry, and the Danish Death Registry including 23, 167 users of calcium channel blockers who received >/=2 prescriptions between January 1, 1989 and December 31, 1995. The authors calculated the standardized incidence ratios and standard mortality ratios for cancer, along with corresponding 95% confidence intervals (95% CI).
RESULTS: Overall, 967 incident cases of cancer occurred, resulting in a standardized incidence ratio of 1.04 (95% CI, 0.98-1.11). There was a slightly elevated nonsignificant risk of tobacco-related cancer. No increased risk of breast or colon carcinoma was observed. The cancer mortality was close to that expected in the background population (standardized mortality ratio of 0.97; 95% CI, 0.89-1.04).
CONCLUSIONS: This large-scale, population-based cohort study adds to the increasing evidence indicating no substantial association between the use of calcium channel blockers and the incidence rate of cancer or cancer mortality. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10897013     DOI: 10.1002/1097-0142(20000701)89:1<165::aid-cncr21>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  26 in total

1.  Use of Antihypertensive Medications and Risk of Adverse Breast Cancer Outcomes in a SEER-Medicare Population.

Authors:  Lu Chen; Jessica Chubak; Denise M Boudreau; William E Barlow; Noel S Weiss; Christopher I Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-08-14       Impact factor: 4.254

Review 2.  Carcinogenicity of antihypertensive therapy.

Authors:  Ehud Grossman; Franz H Messerli; Uri Goldbourt
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

3.  Antihypertensive medication use and incident breast cancer in women.

Authors:  Elizabeth E Devore; Sung Kim; Cody A Ramin; Lani R Wegrzyn; Jennifer Massa; Michelle D Holmes; Karin B Michels; Rulla M Tamimi; John P Forman; Eva S Schernhammer
Journal:  Breast Cancer Res Treat       Date:  2015-02-21       Impact factor: 4.872

4.  Antihypertensive medication use and risk of renal cell carcinoma.

Authors:  Joanne S Colt; Jonathan N Hofmann; Kendra Schwartz; Wong-Ho Chow; Barry I Graubard; Faith Davis; Julie Ruterbusch; Sonja Berndt; Mark P Purdue
Journal:  Cancer Causes Control       Date:  2017-02-21       Impact factor: 2.506

5.  Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk.

Authors:  George A Makar; John H Holmes; Yu-Xiao Yang
Journal:  J Natl Cancer Inst       Date:  2014-01-15       Impact factor: 13.506

6.  Migraine in postmenopausal women and the risk of invasive breast cancer.

Authors:  Robert W Mathes; Kathleen E Malone; Janet R Daling; Scott Davis; Sylvia M Lucas; Peggy L Porter; Christopher I Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

7.  Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years.

Authors:  Christopher I Li; Janet R Daling; Mei-Tzu C Tang; Kara L Haugen; Peggy L Porter; Kathleen E Malone
Journal:  JAMA Intern Med       Date:  2013-09-23       Impact factor: 21.873

Review 8.  The Risk for Lung Cancer Incidence with Calcium Channel Blockers: A Systematic Review and Meta-Analysis of Observational Studies.

Authors:  Victoria Rotshild; Laurent Azoulay; Majd Zarifeh; Reem Masarwa; Bruria Hirsh-Raccah; Amichai Perlman; Mordechai Muszkat; Ilan Matok
Journal:  Drug Saf       Date:  2018-06       Impact factor: 5.606

9.  Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter.

Authors:  Xiaowan Zheng; Sean Ekins; Jean-Pierre Raufman; James E Polli
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

10.  Antihypertensive medications and risks of recurrence and mortality in luminal, triple-negative, and HER2-overexpressing breast cancer.

Authors:  Nicole C Lorona; Linda S Cook; Mei-Tzu C Tang; Deirdre A Hill; Charles L Wiggins; Christopher I Li
Journal:  Cancer Causes Control       Date:  2021-08-04       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.